期刊
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
卷 28, 期 2, 页码 130-135出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/cap.2017.0085
关键词
atomoxetine; parent training; ADHD; sleep disturbance; autism spectrum disorder; clinical trial
资金
- National Institute of Mental Health [1R01MH079080-01A2, 5R01MH079082-05, R01 MH083247]
- University of Rochester CTSA [UL1 RR024160]
- Ohio State University CTSA from the National Center for Research Resources [UL1TR001070]
- National Center for Advancing Translational Sciences of the National Institutes of Health
- Eli Lilly and Company
Objective: Sleep disturbance is often a problem for children with either autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD). Psychostimulant medications used to treat ADHD symptoms can exacerbate this problem. For children with ASD and ADHD, atomoxetine (ATX) is a viable alternative to psychostimulants. We investigated the effects of ATX and a manualized parent training (PT) program targeting noncompliance, on the sleep quality of children with ASD and ADHD. Methods: Participants in a randomized clinical trial were treated with ATX + PT, ATX alone, PT alone, or placebo (PBO) alone, for 10 weeks. Fifty-four of 128 (42%) caregivers completed the Children's Sleep Habits Questionnaire (CSHQ) at baseline and endpoint. Analysis of covariance was used to investigate possible differences between treatment groups. Results: There were no significant differences between treatment groups, including PBO on the CSHQ 33-Item total score, total hours of sleep per day, and total minutes awake after sleep onset at the study endpoint. Conclusion: ATX appears sleep neutral. Clinicians who treat ADHD symptoms in children and adolescents with ASD may prefer ATX over psychostimulants when sleep disturbance is an issue.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据